Personalized medicine and drug hypersensitivities

Personalized medicine and drug hypersensitivities

Personalized medicine is supposed to tailor actions of prevention and treatments to individual patient data. Personalized medicine is a challenge in the drug allergy/hypersensitivity field. If most interventions in drug allergy work-up have long been quite empirical (the patients being therefore tes...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Revue française d'allergologie (2009) 2020-12, Vol.60 (8), p.21-25
1. Verfasser: Chiriac, A. M.
Format: Artikel
Sprache:eng ; fre
Schlagworte:
Allergy
Life Sciences & Biomedicine
Science & Technology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 25
container_issue 8
container_start_page 21
container_title Revue française d'allergologie (2009)
container_volume 60
creator Chiriac, A. M.
description Personalized medicine is supposed to tailor actions of prevention and treatments to individual patient data. Personalized medicine is a challenge in the drug allergy/hypersensitivity field. If most interventions in drug allergy work-up have long been quite empirical (the patients being therefore tested more or less in the same way), the last decade has brought to light a bulk of data ensuing better risk stratification of patients. Therefore, changes occur in all fields of the so-called 6P medicine: personalized, preventive, predictive, based on proofs, participative and taking into account the patient's medical pathway. This paper addresses some of these changes, in order to bring to light recent progress in drug allergy work-up. (C) 2020 Elsevier Masson SAS. All rights reserved.
doi_str_mv 10.1016/S1877-0320(20)30482-6
format Article
fullrecord <record><control><sourceid>webofscience</sourceid><recordid>TN_cdi_webofscience_primary_000600791900005</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>000600791900005</sourcerecordid><originalsourceid>FETCH-LOGICAL-s155t-24ca5dff2d8715851116ed8c0f6f6e1752c85e211c5dcae027c80d92e4d789b53</originalsourceid><addsrcrecordid>eNqNj1tLAzEQhfOgYKn9CcI-KrI6k91c9lEWb1CwUH0uaTLRSJstm1Spv95dFJ8dOAwcPg58jJ0hXCGgvF6iVqqEisM5h4sKas1LecQmf_UJm6X0DuMp4BInDBfUpy6aTfgiV2zJBRsiFSa6wvX71-LtsBsAiink8DGE0ik79maTaPb7p-zl7va5fSjnT_eP7c28TChELnltjXDec6cVCi0QUZLTFrz0klAJbrUgjmiFs4aAK6vBNZxqp3SzFtWUXf7sftK688kGipZWuz5sTX9YDQZykGiwGWVGWv-fbkM2OXSx7fYxV9_v21rq</addsrcrecordid><sourcetype>Enrichment Source</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Personalized medicine and drug hypersensitivities</title><source>Web of Science - Science Citation Index Expanded - 2020&lt;img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /&gt;</source><source>Access via ScienceDirect (Elsevier)</source><creator>Chiriac, A. M.</creator><creatorcontrib>Chiriac, A. M.</creatorcontrib><description>Personalized medicine is supposed to tailor actions of prevention and treatments to individual patient data. Personalized medicine is a challenge in the drug allergy/hypersensitivity field. If most interventions in drug allergy work-up have long been quite empirical (the patients being therefore tested more or less in the same way), the last decade has brought to light a bulk of data ensuing better risk stratification of patients. Therefore, changes occur in all fields of the so-called 6P medicine: personalized, preventive, predictive, based on proofs, participative and taking into account the patient's medical pathway. This paper addresses some of these changes, in order to bring to light recent progress in drug allergy work-up. (C) 2020 Elsevier Masson SAS. All rights reserved.</description><identifier>ISSN: 1877-0320</identifier><identifier>DOI: 10.1016/S1877-0320(20)30482-6</identifier><language>eng ; fre</language><publisher>PARIS: Elsevier</publisher><subject>Allergy ; Life Sciences &amp; Biomedicine ; Science &amp; Technology</subject><ispartof>Revue française d'allergologie (2009), 2020-12, Vol.60 (8), p.21-25</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>0</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000600791900005</woscitedreferencesoriginalsourcerecordid><cites>FETCH-LOGICAL-s155t-24ca5dff2d8715851116ed8c0f6f6e1752c85e211c5dcae027c80d92e4d789b53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27933,27934,28257</link.rule.ids></links><search><creatorcontrib>Chiriac, A. M.</creatorcontrib><title>Personalized medicine and drug hypersensitivities</title><title>Revue française d'allergologie (2009)</title><addtitle>REV FR ALLERGOL</addtitle><description>Personalized medicine is supposed to tailor actions of prevention and treatments to individual patient data. Personalized medicine is a challenge in the drug allergy/hypersensitivity field. If most interventions in drug allergy work-up have long been quite empirical (the patients being therefore tested more or less in the same way), the last decade has brought to light a bulk of data ensuing better risk stratification of patients. Therefore, changes occur in all fields of the so-called 6P medicine: personalized, preventive, predictive, based on proofs, participative and taking into account the patient's medical pathway. This paper addresses some of these changes, in order to bring to light recent progress in drug allergy work-up. (C) 2020 Elsevier Masson SAS. All rights reserved.</description><subject>Allergy</subject><subject>Life Sciences &amp; Biomedicine</subject><subject>Science &amp; Technology</subject><issn>1877-0320</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><recordid>eNqNj1tLAzEQhfOgYKn9CcI-KrI6k91c9lEWb1CwUH0uaTLRSJstm1Spv95dFJ8dOAwcPg58jJ0hXCGgvF6iVqqEisM5h4sKas1LecQmf_UJm6X0DuMp4BInDBfUpy6aTfgiV2zJBRsiFSa6wvX71-LtsBsAiink8DGE0ik79maTaPb7p-zl7va5fSjnT_eP7c28TChELnltjXDec6cVCi0QUZLTFrz0klAJbrUgjmiFs4aAK6vBNZxqp3SzFtWUXf7sftK688kGipZWuz5sTX9YDQZykGiwGWVGWv-fbkM2OXSx7fYxV9_v21rq</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Chiriac, A. M.</creator><general>Elsevier</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope></search><sort><creationdate>20201201</creationdate><title>Personalized medicine and drug hypersensitivities</title><author>Chiriac, A. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-s155t-24ca5dff2d8715851116ed8c0f6f6e1752c85e211c5dcae027c80d92e4d789b53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; fre</language><creationdate>2020</creationdate><topic>Allergy</topic><topic>Life Sciences &amp; Biomedicine</topic><topic>Science &amp; Technology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chiriac, A. M.</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><jtitle>Revue française d'allergologie (2009)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chiriac, A. M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Personalized medicine and drug hypersensitivities</atitle><jtitle>Revue française d'allergologie (2009)</jtitle><stitle>REV FR ALLERGOL</stitle><date>2020-12-01</date><risdate>2020</risdate><volume>60</volume><issue>8</issue><spage>21</spage><epage>25</epage><pages>21-25</pages><issn>1877-0320</issn><abstract>Personalized medicine is supposed to tailor actions of prevention and treatments to individual patient data. Personalized medicine is a challenge in the drug allergy/hypersensitivity field. If most interventions in drug allergy work-up have long been quite empirical (the patients being therefore tested more or less in the same way), the last decade has brought to light a bulk of data ensuing better risk stratification of patients. Therefore, changes occur in all fields of the so-called 6P medicine: personalized, preventive, predictive, based on proofs, participative and taking into account the patient's medical pathway. This paper addresses some of these changes, in order to bring to light recent progress in drug allergy work-up. (C) 2020 Elsevier Masson SAS. All rights reserved.</abstract><cop>PARIS</cop><pub>Elsevier</pub><doi>10.1016/S1877-0320(20)30482-6</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1877-0320
ispartof Revue française d'allergologie (2009), 2020-12, Vol.60 (8), p.21-25
issn 1877-0320
language eng ; fre
recordid cdi_webofscience_primary_000600791900005
source Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; Access via ScienceDirect (Elsevier)
subjects Allergy
Life Sciences & Biomedicine
Science & Technology
title Personalized medicine and drug hypersensitivities
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-01T05%3A52%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-webofscience&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Personalized%20medicine%20and%20drug%20hypersensitivities&rft.jtitle=Revue%20franc%CC%A7aise%20d'allergologie%20(2009)&rft.au=Chiriac,%20A.%20M.&rft.date=2020-12-01&rft.volume=60&rft.issue=8&rft.spage=21&rft.epage=25&rft.pages=21-25&rft.issn=1877-0320&rft_id=info:doi/10.1016/S1877-0320(20)30482-6&rft_dat=%3Cwebofscience%3E000600791900005%3C/webofscience%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true